{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:53:56Z","timestamp":1767650036729},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"992","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Bisphosphonates reduce the rate of bone resorption and bone remodelling. Given daily, they decrease the risk of fractures in postmenopausal osteoporosis. When bisphosphonates were given at extended drug-free intervals this antifracture efficacy was generally not seen. This may be due to the different pattern of bone remodelling changes. Data from randomised clinical studies of ibandronate, given orally or intravenously, at different doses and for variable time intervals to women with osteoporosis were examined to explore the relationship between intermittent bisphosphonate therapy, changes in bone resorption and fracture risk. The magnitude of the reduction of the rate of bone resorption at the end of the drug-free interval rather than its fluctuation pattern after bisphosphonate administration determines antifracture efficacy, provided that these fluctuations occur within the premenopausal range. Prolongation of the drug-free interval beyond 2 weeks should be compensated by a dose higher than the cumulative daily dose.<\/jats:p>","DOI":"10.1136\/ard.2006.064931","type":"journal-article","created":{"date-parts":[[2007,2,4]],"date-time":"2007-02-04T01:47:45Z","timestamp":1170553665000},"page":"307-312","source":"Crossref","is-referenced-by-count":1,"title":["Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate"],"prefix":"10.1093","volume":"84","author":[{"given":"S E","family":"Papapoulos","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases, Leiden University Medical Centre , Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R C","family":"Schimmer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases, F Hoffmann-La Roche Ltd , Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2008,7,21]]},"reference":[{"key":"2023041909450130300_bib1","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2023041909450130300_bib2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2023041909450130300_bib3","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2023041909450130300_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"2023041909450130300_bib5","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial, FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2023041909450130300_bib6","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"2023041909450130300_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporosis Int"},{"key":"2023041909450130300_bib8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"2023041909450130300_bib9","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Metaanalysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"2023041909450130300_bib10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","article-title":"Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"2023041909450130300_bib11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00198-004-1725-z","article-title":"Metaanalysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women","volume":"16","author":"Papapoulos","year":"2005","journal-title":"Osteoporosis Int"},{"key":"2023041909450130300_bib12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1359\/jbmr.2002.17.6.1057","article-title":"Daily oral pamidronate in women and men with osteoporosis: a 3-year randomised, placebo-controlled clinical trial with a 2-year extension","volume":"17","author":"Brumsen","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2023041909450130300_bib13","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1359\/jbmr.040116","article-title":"Clodronate reduces vertebral fracture risk in women with postmenopausal osteoporosis: results of a double-blind, placebo-controlled 3-year study","volume":"19","author":"McCloskey","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2023041909450130300_bib14","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2023041909450130300_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00223-002-2104-4","article-title":"Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography","volume":"73","author":"Dufresne","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"2023041909450130300_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1185\/030079904X20259","article-title":"Trabecular bone microarchitecture after alendronate treatment of osteoporotic women","volume":"21","author":"Recker","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"2023041909450130300_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S8756-3282(01)00485-9","article-title":"Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women","volume":"29","author":"Roschger","year":"2001","journal-title":"Bone"},{"key":"2023041909450130300_bib18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone"},{"key":"2023041909450130300_bib19","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bone.2003.12.013","article-title":"Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography","volume":"34","author":"Borah","year":"2004","journal-title":"Bone"},{"key":"2023041909450130300_bib20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","article-title":"The impact of compliance with osteoporosis therapy on fracture rates in actual practice","volume":"15","author":"Caro","year":"2004","journal-title":"Osteoporosis Int"},{"key":"2023041909450130300_bib21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"2023041909450130300_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging Clin Exp Res"},{"key":"2023041909450130300_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"2023041909450130300_bib24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","article-title":"Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis","volume":"21","author":"Cramer","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"2023041909450130300_bib25","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4065\/80.7.856","article-title":"Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women","volume":"80","author":"Recker","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"2023041909450130300_bib26","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","article-title":"Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomised, open-label, crossover study","volume":"24","author":"Simon","year":"2002","journal-title":"Clin Ther"},{"key":"2023041909450130300_bib27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.maturitas.2003.12.012","article-title":"Patients with osteoporosis prefer once weekly to once daily dosing with alendronate","volume":"48","author":"Kendler","year":"2004","journal-title":"Maturitas"},{"key":"2023041909450130300_bib28","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1185\/030079905X74862","article-title":"Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis","volume":"21","author":"Emkey","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"2023041909450130300_bib29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0002-9343(93)90350-X","article-title":"Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy","volume":"95","author":"Harris","year":"1993","journal-title":"Am J Med"},{"key":"2023041909450130300_bib30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s001980170126","article-title":"Intermittent cyclic tiludronate in the treatment of osteoporosis","volume":"12","author":"Reginster","year":"2001","journal-title":"Osteoporosis Int"},{"key":"2023041909450130300_bib31","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis","volume":"34","author":"Recker","year":"2004","journal-title":"Bone"},{"key":"2023041909450130300_bib32","first-page":"115","article-title":"Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev"},{"key":"2023041909450130300_bib33","first-page":"711","article-title":"Nitrogen-containing bisphosphonate mechanism of action","volume":"4","author":"Reszka","year":"2004","journal-title":"Mini Rev Med Chem"},{"key":"2023041909450130300_bib34","first-page":"196","article-title":"New insights into the molecular mechanism of action of bisphosphonates","volume":"11","author":"Rogers","year":"2003","journal-title":"Curr Pharm Res"},{"key":"2023041909450130300_bib35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/8756-3282(96)00182-2","article-title":"Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones","volume":"19","author":"Masarachia","year":"1996","journal-title":"Bone"},{"key":"2023041909450130300_bib36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"2023041909450130300_bib37","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporosis Int"},{"key":"2023041909450130300_bib38","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstrom","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"2023041909450130300_bib39","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2023041909450130300_bib40","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2023041909450130300_bib41","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2023041909450130300_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0149-2918(00)87974-6","article-title":"Weekly administration of alendronate: rationale and plan for clinical assessment","volume":"22","author":"Bone","year":"2000","journal-title":"Clin Ther"},{"key":"2023041909450130300_bib43","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","article-title":"Pharmacokinetics\/pharmacodynamics of bisphosphonates: use for optimization of intermittent therapy for osteoporosis","volume":"44","author":"Cremers","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2023041909450130300_bib44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis","volume":"323","author":"Watts","year":"1990","journal-title":"N Engl J Med"},{"key":"2023041909450130300_bib45","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF01623227","article-title":"Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride in osteoporosis occurring in the menopause","volume":"4","author":"Thiebaud","year":"1994","journal-title":"Osteoporosis Int"},{"key":"2023041909450130300_bib46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0169-6009(91)90129-N","article-title":"Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis","volume":"15","author":"Passeri","year":"1991","journal-title":"Bone Miner"},{"key":"2023041909450130300_bib47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S8756-3282(00)00291-X","article-title":"Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis","volume":"27","author":"Rossini","year":"2000","journal-title":"Bone"},{"key":"2023041909450130300_bib48","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S8756-3282(03)00084-X","article-title":"Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis","volume":"33","author":"Braga","year":"2003","journal-title":"Bone"},{"key":"2023041909450130300_bib49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/PL00004179","article-title":"Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety","volume":"11","author":"Ryan","year":"2000","journal-title":"Osteoporosis Int"},{"key":"2023041909450130300_bib50","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/PL00004152","article-title":"A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis","volume":"7","author":"Clemmesen","year":"1997","journal-title":"Osteoporosis Int"},{"key":"2023041909450130300_bib51","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"2023041909450130300_bib52","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2023041909450130300_bib53","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"Thiebaud","year":"1997","journal-title":"Am J Med"},{"key":"2023041909450130300_bib54","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","article-title":"Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis","volume":"16","author":"Riis","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2023041909450130300_bib55","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1359\/jbmr.2002.17.9.1662","article-title":"Long-term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing","volume":"17","author":"Hernandez","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2023041909450130300_bib56","first-page":"S97","article-title":"Successful prediction of biomarker response to oral monthly ibandronate [abstract]","volume":"15","author":"Gieschke","year":"2004","journal-title":"Osteoporosis Int"},{"key":"2023041909450130300_bib57","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1210\/jc.2004-1750","article-title":"Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study","volume":"90","author":"Reginster","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 1","key":"2023041909450130300_bib58","first-page":"S164","article-title":"Week-by-week effects of monthly ibandronate on biochemical markers of bone resorption: results of a 3-month randomized trial [abstract]","volume":"78","author":"Geusens","year":"2006","journal-title":"Calcif Tissue Int"},{"key":"2023041909450130300_bib59","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2023041909450130300_bib60","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2023041909450130300_bib61","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by intravenous injection once every 3 months","volume":"34","author":"Adami","year":"2004","journal-title":"Bone"},{"key":"2023041909450130300_bib62","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00198-003-1409-0","article-title":"Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate","volume":"14","author":"Christiansen","year":"2003","journal-title":"Osteoporosis Int"},{"key":"2023041909450130300_bib63","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023041909450130300_bib64","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2023041909450130300_bib65","first-page":"990","article-title":"Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J Rheumatol"},{"key":"2023041909450130300_bib66","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporosis Int"},{"key":"2023041909450130300_bib67","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"2023041909450130300_bib68","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bone.2006.01.141","article-title":"Mechanisms of action of bisphosphonates: physical chemistry revisited","volume":"38","author":"Papapoulos","year":"2006","journal-title":"Bone"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/84\/992\/307\/50021902\/postgradmedj-84-307.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/84\/992\/307\/50021902\/postgradmedj-84-307.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T09:55:37Z","timestamp":1681898137000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/84\/992\/307\/7023534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,1]]},"references-count":68,"journal-issue":{"issue":"992","published-online":{"date-parts":[[2008,7,21]]},"published-print":{"date-parts":[[2008,6,1]]}},"URL":"https:\/\/doi.org\/10.1136\/ard.2006.064931","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,6]]},"published":{"date-parts":[[2008,6,1]]}}}